In this video entitled “Traitement Adjuvant après chirurgie du Cancer du Rein”, Professors Pierre Bigot and Jean-Christophe Bernhard present the latest recommendations from the Oncology Committee of the French Association of Urology (CCAFU) regarding adjuvant treatment for kidney cancer.
The discussion explores recent evolutions in this field, explaining the reasons of these changes and their impact on patient selection. The speakers, Prof. Pierre Bigot and Prof. Jean-Christophe Bernhard, also address the administration of pembrolizumab as an adjuvant therapy, the management of related side effects, ongoing clinical studies, and future directions in the postoperative management of localised kidney cancer.
We would like to thank the French Association of Urology for its commitment to the ADAPT-RCC project, which has granted a budget to evaluate adjuvant treatment and personalised management of patients with localised or locally advanced kidney cancer.
The ADAPT-RCC project is led by Prof. Jean-Christophe Bernhard and Dr Gaëlle Margue (Principal investigator for this trial for CCAFU-Rein).
The video is available on Fréquence Médicale website.
ADAPT-RCC project:
Methodology:
13 UroCCR centres
2,974 patients
3 cohort studies
Artificial intelligence and biomarker research
Challenges:
De-escalation of therapy and surveillance in patients with a better prognosis;
Intensification of treatment in patients who may require an adjuvant treatment;
Improvement of the quality of clinical information for both surgical teams and in interactions with patients.
Objective:
–> Enhancing the quality of postoperative management recommendations for localised or locally advanced kidney cancer with:
– The validation of the UroPredict 2 Machine Learning algorithm
– The evaluation of the KIM-1 biomarker (prognosis, prediction)
Design : JUUD l’agence – Rédactionnel : Le Monde selon vous – Développement : Ideclap – Traduction : Krushenka LUPARELLI
